What is Orasis Pharmaceuticals?
Orasis Pharmaceuticals is a specialized ophthalmic pharmaceutical enterprise dedicated to addressing unmet needs in vision care. The company is best known for the development and FDA approval of QLOSI, a prescription eye drop designed to treat presbyopia. By providing a pharmacological alternative to traditional reading glasses, Orasis is effectively challenging established paradigms in the eye care industry. The company's market position is bolstered by a robust pipeline and a strategic focus on high-impact, patient-centric medical solutions that improve quality of life for aging populations.
How much funding has Orasis Pharmaceuticals raised?
Orasis Pharmaceuticals has raised a total of $126M across 4 funding rounds:
Series B
$13M
Series C
$30M
Debt
$15M
Series D
$68M
Series B (2018): $13M with participation from Visionary Ventures
Series C (2020): $30M led by Maverick Ventures, LifeSci Venture Partners, Bluestem Capital, SBI Innovation Fund, Visionary Ventures, and Steamboat Ventures
Series D (2024): $68M supported by Johnson & Johnson Innovation and Arboretum Ventures
Debt (2024): $15M featuring Catalio Capital Management
Key Investors in Orasis Pharmaceuticals
Johnson & Johnson Innovation
A global leader in healthcare innovation that partners with early-stage businesses to develop transformational solutions across pharmaceuticals, medical devices, and consumer health.
Arboretum Ventures
A Midwest-based venture capital firm specializing in healthcare, with a focus on medical devices and life science tools that improve patient outcomes and reduce costs.
Catalio Capital Management
A New York-based investment firm that focuses on breakthrough biomedical technology, leveraging a deep network of venture partners to support companies across private and public markets.
What's next for Orasis Pharmaceuticals?
With the recent infusion of $68M, Orasis Pharmaceuticals is well-positioned to accelerate the commercial rollout of its lead product while exploring further indications within the ophthalmology space. The company's strategic roadmap likely involves scaling its supply chain, enhancing market penetration, and leveraging its clinical data to secure broader adoption among eye care professionals. As the firm moves into this next phase of growth, the focus will shift toward operational excellence and long-term value creation for stakeholders, supported by a syndicate of high-profile investors committed to the advancement of biomedical technology.
See full Orasis Pharmaceuticals company page
